Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Wu, Joseph C  [Clear All Filters]
2020
Chandy M, Rhee J-W, Ozen MO, Williams DR, Pepic L, Liu C, Zhang H, Malisa J, Lau E, Demirci U, et al. Atlas of Exosomal microRNAs Secreted From Human iPSC-Derived Cardiac Cell Types. Circulation. 2020;142(18):1794-1796.
Kernik DC, Yang P-C, Kurokawa J, Wu JC, Clancy CE. A computational model of induced pluripotent stem-cell derived cardiomyocytes for high throughput risk stratification of KCNQ1 genetic variants. PLoS Comput Biol. 2020;16(8):e1008109.
Ramachandra CJA, Chua J, Cong S, Kp MMai Ja, Shim W, Wu JC, Hausenloy DJ. Human induced pluripotent stem cells for modelling metabolic perturbations and impaired bioenergetics underlying cardiomyopathies. Cardiovasc Res. 2020.
Obal D, Wu JC. Induced Pluripotent Stem Cells as a Platform to Understand Patient-Specific Responses to Opioids and Anaesthetics. Br J Pharmacol. 2020.
Miao Y, Tian L, Martin M, Paige SL, Galdos FX, Li J, Klein A, Zhang H, Ma N, Wei Y, et al. Intrinsic Endocardial Defects Contribute to Hypoplastic Left Heart Syndrome. Cell Stem Cell. 2020.
Feyen DAM, McKeithan WL, Bruyneel AAN, Spiering S, Hörmann L, Ulmer B, Zhang H, Briganti F, Schweizer M, Hegyi B, et al. Metabolic Maturation Media Improve Physiological Function of Human iPSC-Derived Cardiomyocytes. Cell Rep. 2020;32(3):107925.
Rhee J-W, Yi H, Thomas D, Lam CKeung, Belbachir N, Tian L, Qin X, Malisa J, Lau E, Paik DT, et al. Modeling Secondary Iron Overload Cardiomyopathy with Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Cell Rep. 2020;32(2):107886.
Jabart E, Molho J, Sin K, Stansfield B, Kazmouz SG, Ventro D, Gardner K, Wu JC, Churko JM. Single-cell protein expression of hiPSC-derived cardiomyocytes using Single-Cell Westerns. J Mol Cell Cardiol. 2020.
Buikema JW, Lee S, Goodyer WR, Maas RG, Chirikian O, Li G, Miao Y, Paige SL, Lee D, Wu H, et al. Wnt Activation and Reduced Cell-Cell Contact Synergistically Induce Massive Expansion of Functional Human iPSC-Derived Cardiomyocytes. Cell Stem Cell. 2020;27(1):50-63.e5.
2019
Kernik DC, Morotti S, Wu H, Garg P, Duff HJ, Kurokawa J, Jalife J, Wu JC, Grandi E, Clancy CE. A computational model of induced pluripotent stem-cell derived cardiomyocytes incorporating experimental variability from multiple data sources. J Physiol. 2019.
Williams IM, Wu JC. Generation of Endothelial Cells From Human Pluripotent Stem Cells. Arterioscler Thromb Vasc Biol. 2019;39(7):1317-1329.
Wang L, Pegram MD, Wu JC. Induced Pluripotent Stem Cells as a Novel Cancer Vaccine. Expert Opin Biol Ther. 2019.
Wu H, Yang H, Rhee J-W, Zhang JZ, Lam CKeung, Sallam K, C Y Chang A, Ma N, Lee J, Zhang H, et al. Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients. Eur Heart J. 2019.
Smith A, Choi E, Gray K, Macadangdang J, Ahn EHyun, Clark EC, Laflamme M, Wu JC, Murry CE, Tung L, et al. NanoMEA: a tool for high-throughput, electrophysiological phenotyping of patterned excitable cells. Nano Lett. 2019.
Lau E, Han Y, Williams DR, Thomas CT, Shrestha R, Wu JC, P Y Lam M. Splice-Junction-Based Mapping of Alternative Isoforms in the Human Proteome. Cell Rep. 2019;29(11):3751-3765.e5.
Wu JC, Garg P, Yoshida Y, Yamanaka S, Gepstein L, Hulot J-S, Knollmann BC, Schwartz PJ. Towards Precision Medicine With Human iPSCs for Cardiac Channelopathies. Circ Res. 2019;125(6):653-658.
Abi-Gerges N, McMahon C, Vargas H, Sager P, Chui R, Stevens D, Davila J, Schaub JR, Wu JC, Del Rio C, et al. The West coast regional safety pharmacology society meeting update: Filling translational gaps in safety assessment. J Pharmacol Toxicol Methods. 2019:106582.
Pang L, Sager P, Yang X, Shi H, Sannajust F, Brock M, Wu JC, Abi-Gerges N, Lyn-Cook B, Berridge BR, et al. Workshop Report: FDA Workshop on Improving Cardiotoxicity Assessment With Human-Relevant Platforms. Circ Res. 2019;125(9):855-867.
2018
Lam CKeung, Wu JC. Disease modelling and drug discovery for hypertrophic cardiomyopathy using pluripotent stem cells: how far have we come?. Eur Heart J. 2018.
Garg P, Oikonomopoulos A, Chen H, Li Y, Lam CKeung, Sallam K, Perez M, Lux RL, Sanguinetti MC, Wu JC. Genome Editing of Induced Pluripotent Stem Cells to Decipher Cardiac Channelopathy Variant. J Am Coll Cardiol. 2018;72(1):62-75.
Wnorowski A, Yang H, Wu JC. Progress, obstacles, and limitations in the use of stem cells in organ-on-a-chip models. Adv Drug Deliv Rev. 2018.
Lau E, Paik DT, Wu JC. Systems-Wide Approaches in Induced Pluripotent Stem Cell Models. Annu Rev Pathol. 2018.
2016
Nguyen PK, Rhee J-W, Wu JC. Adult Stem Cell Therapy and Heart Failure, 2000 to 2016: A Systematic Review. JAMA Cardiol. 2016.
Burridge PW, Li YFuga, Matsa E, Wu H, Ong S-G, Sharma A, Holmström A, Chang AC, Coronado MJ, Ebert AD, et al. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat Med. 2016.
Chanana AM, Rhee J-W, Wu JC. Human-induced pluripotent stem cell approaches to model inborn and acquired metabolic heart diseases. Curr Opin Cardiol. 2016.

Pages